DaVita Inc. (NYSE:DVA - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $126.96 and last traded at $126.18, with a volume of 654514 shares. The stock had previously closed at $140.52.
Analysts Set New Price Targets
Several research firms have weighed in on DVA. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Truist Financial lowered their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday, May 19th. Finally, Barclays decreased their target price on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research note on Thursday. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, DaVita presently has a consensus rating of "Hold" and an average target price of $170.75.
Read Our Latest Analysis on DVA
DaVita Price Performance
The firm has a market capitalization of $9.30 billion, a PE ratio of 12.81, a P/E/G ratio of 0.88 and a beta of 1.09. The firm's fifty day moving average price is $140.15 and its 200 day moving average price is $147.07. The company has a current ratio of 1.39, a quick ratio of 1.20 and a debt-to-equity ratio of 23.18.
DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%. The firm had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same period last year, the business posted $2.00 earnings per share. DaVita's revenue was up 6.1% compared to the same quarter last year. As a group, equities analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.
Insider Buying and Selling
In related news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares of the company's stock, valued at approximately $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.00% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. boosted its position in shares of DaVita by 4.2% in the second quarter. PNC Financial Services Group Inc. now owns 13,831 shares of the company's stock worth $1,970,000 after buying an additional 558 shares during the period. Forsta AP Fonden grew its stake in DaVita by 44.2% during the second quarter. Forsta AP Fonden now owns 28,700 shares of the company's stock worth $4,088,000 after buying an additional 8,800 shares during the last quarter. KBC Group NV grew its holdings in DaVita by 38.7% during the 2nd quarter. KBC Group NV now owns 374,749 shares of the company's stock worth $53,383,000 after acquiring an additional 104,554 shares during the last quarter. Wealth Quarterback LLC increased its position in DaVita by 6.0% in the second quarter. Wealth Quarterback LLC now owns 5,301 shares of the company's stock worth $755,000 after purchasing an additional 298 shares during the period. Finally, Verus Capital Partners LLC boosted its position in shares of DaVita by 15.3% in the 2nd quarter. Verus Capital Partners LLC now owns 2,345 shares of the company's stock worth $334,000 after purchasing an additional 311 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.
DaVita Company Profile
(
Get Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.